Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
April 08, 2024 07:00 ET
|
Marker Therapeutics
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada ...
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
March 25, 2024 17:45 ET
|
Marker Therapeutics
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR...
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
January 22, 2024 07:30 ET
|
Marker Therapeutics
HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
May 31, 2023 06:30 ET
|
Marker Therapeutics
HOUSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
March 22, 2023 08:10 ET
|
Marker Therapeutics
2022 CLINICAL AND REGULATORY HIGHLIGHTS Awarded $2 million grant from U.S. Food and Drug Administration (FDA) for the Phase 2 ARTEMIS trial of MT-401 in post-transplant acute myeloid leukemia...
Aegis Sciences Announces CDC Contract to Provide Genomic Sequencing of SARS-CoV-2 to Aid Public Health Response to COVID-19
March 16, 2021 09:00 ET
|
Aegis Sciences Corporation
NASHVILLE, Tenn., March 16, 2021 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative COVID-19 and medication compliance testing services,...
Historical marker to commemorate Dr. King’s final flight
March 29, 2017 16:00 ET
|
First Horizon National Corporation
MEMPHIS, Tenn., March 29, 2017 (GLOBE NEWSWIRE) -- A historical marker commemorating the final flight of Dr. Martin Luther King Jr. will be dedicated at Memphis International Airport on April 3....
Applied DNA Sciences Signs Global Luxury Brand Agreement
January 07, 2010 08:30 ET
|
Applied DNA Sciences, Inc.
STONY BROOK, NY--(Marketwire - January 7, 2010) - Applied DNA Sciences (OTCBB: APDN)
announced that it has signed an exclusive Supply Agreement with a renowned
luxury brand with global distribution,...
Applied DNA Sciences Files Patent for SigNature DNA in Cyanoacrylate to Add Forensic Layer of Anti-Counterfeit Security
May 14, 2009 08:30 ET
|
Applied DNA Sciences, Inc.
STONY BROOK, NY--(Marketwire - May 14, 2009) - Applied DNA Sciences, Inc. (OTCBB: APDN), a
provider of DNA-based security solutions, announced today that it has filed
a patent for the embedment of...